vice-professor
Tianjin medical university general hospital hematoloy department, China (People's Republic)
Zhaoyun Liu，MD,Vice professor，Tianjin medical university general hospital.
since 2013, the applicant has been dedicated to researching the immunopathogenesis of MM and medical nanomaterials. Guided by the clinical needs of patient treatment and condition assessment, and striving for originality, the applicant has made scientific research achievements in three aspects of "immunological mechanisms," "immunotherapy," and "efficacy and prognosis assessment" regarding MM recurrence mechanisms from an immunological perspective:① Revealed the mechanism by which mesenchymal stem cells promote the formation of an inhibitory immune microenvironment in MM through TIGIT and other factors;② Based on this, established a systematic (tumor-immunity-microenvironment) translational application model of immunotherapy using AIE nanomaterials to reprogram the immunogenicity of tumor cells to activate anti-tumor immune responses, regulate TIGIT expression to restore immune function, and intervene in immune cell inhibition by lactate in the immune microenvironment;③ Clinically constructed a comprehensive condition monitoring platform based on MM immune status (zero-cost immune monitoring platform), tumor burden (tumor cell-derived microvesicle detection platform), and complications.
These research achievements propose new methods for immunotherapy and comprehensive condition assessment in MM patients, significantly prolonging their overall survival time. The achievements have been applied in over 5,000 patients across 21 tertiary grade A hospitals nationwide, including Peking University People's Hospital, and the "zero-cost detection platform" has saved nearly 1 million yuan in medical insurance funds cumulatively.
In the past five years, as the first author or corresponding author, the applicant has published 43 papers in journals such as Advanced Materials and American Journal of Hematology. The original research achievements have received 2 first-class provincial and ministerial science and technology awards, 1 second-class award, 2 national invention patents, 4 utility model patents, and other honors. Through innovative work on "immunopathogenesis and clinical translational application of MM patients," a distinct research characteristic and clinical translational application paradigm have been gradually formed.